Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tobias Zeller

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Swiss Dental Journal|February 27, 2026
[Multiple root resorptions with ankylosis]Tobias Zeller, Ralf Schulze, Philippe Biel, et al.
Clinical and Experimental Immunology|March 24, 2022
Immunotherapeutic targeting of activating natural killer cell receptors and their ligands in cancerMatthias Peipp, Katja Klausz, Ammelie Svea Boje, et al.
Frontiers in Immunology|October 2, 2023
Perspectives of targeting LILRB1 in innate and adaptive immune checkpoint therapy of cancerTobias Zeller, Ira A Münnich, Roland Windisch, et al.
Hemasphere|March 4, 2024
Enhanced potency of immunotherapy against B-cell precursor acute lymphoblastic leukemia by combination of an Fc-engineered CD19 antibody and CD47 blockadeDenis M Schewe, Fotini Vogiatzi, Ira A Münnich, et al.
Frontiers in Immunology|November 17, 2022
Dual checkpoint blockade of CD47 and LILRB1 enhances CD20 antibody-dependent phagocytosis of lymphoma cells by macrophagesTobias Zeller, Sebastian Lutz, Ira A Münnich, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Swiss Dental Journal|February 27, 2026
[Multiple root resorptions with ankylosis]Tobias Zeller, Ralf Schulze, Philippe Biel, et al.
Clinical and Experimental Immunology|March 24, 2022
Immunotherapeutic targeting of activating natural killer cell receptors and their ligands in cancerMatthias Peipp, Katja Klausz, Ammelie Svea Boje, et al.
Frontiers in Immunology|October 2, 2023
Perspectives of targeting LILRB1 in innate and adaptive immune checkpoint therapy of cancerTobias Zeller, Ira A Münnich, Roland Windisch, et al.
Hemasphere|March 4, 2024
Enhanced potency of immunotherapy against B-cell precursor acute lymphoblastic leukemia by combination of an Fc-engineered CD19 antibody and CD47 blockadeDenis M Schewe, Fotini Vogiatzi, Ira A Münnich, et al.
Frontiers in Immunology|November 17, 2022
Dual checkpoint blockade of CD47 and LILRB1 enhances CD20 antibody-dependent phagocytosis of lymphoma cells by macrophagesTobias Zeller, Sebastian Lutz, Ira A Münnich, et al.
Pageof 1